Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | TYR | P14679 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.51 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.51 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.51 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.50 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.50 |
| ▸ | GJA1 | P17302 | 1/20 | 0.50 |
| ▸ | GJB2 | P29033 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trehalose SCHEMBL14472517 | 1.00 | MEN1 (0.57) | MEN1KMT2APTPN1L3MBTL1GAA | |
| Trehalose SCHEMBL13465987 | 1.00 | MEN1 (0.57) | MEN1KMT2APTPN1L3MBTL1GAA | |
| SCHEMBL5316713 | 1.00 | MEN1 (0.57) | MEN1KMT2APTPN1L3MBTL1GAA | |
| Trehalose SCHEMBL25304700 | 1.00 | MEN1 (0.57) | MEN1KMT2APTPN1L3MBTL1GAA | |
| Trehalose SCHEMBL17072366 | 1.00 | MEN1 (0.57) | MEN1KMT2APTPN1L3MBTL1GAA | |
| Trehalose SCHEMBL23029503 | 1.00 | MEN1 (0.57) | MEN1KMT2APTPN1L3MBTL1GAA | |
| SCHEMBL5399869 | 1.00 | MEN1 (0.57) | MEN1KMT2APTPN1L3MBTL1GAA | |
| Trehalose SCHEMBL17072437 | 1.00 | MEN1 (0.57) | MEN1KMT2APTPN1L3MBTL1GAA | |
| Trehalose SCHEMBL670041 | 1.00 | MEN1 (0.57) | MEN1KMT2APTPN1L3MBTL1GAA | |
| Trehalose SCHEMBL15497371 | 1.00 | MEN1 (0.57) | MEN1KMT2APTPN1L3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 688 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023067675-A1 | ORAL COMPOSITION CONTAINING TREHALOSE | 日本たばこ産業株式会社 | 2023-04-27 | — | — | WO | claimed |
| US-20220154137-A1 | CELL CULTURE MEDIUM | AGENCY FOR SCIENCE, TECHNOLOGY AND REASEARCH (SG) | 2022-05-19 | — | — | US | claimed |
| US-20210355454-A1 | SYSTEMS AND METHODS FOR PRODUCING GENE THERAPY FORMULATIONS | VOYAGER THERAPEUTICS, INC. | 2021-11-18 | — | — | US | claimed |
| US-11160766-B2 | Peritoneal therapeutic fluid | OPTERION HEALTH AG (CH) | 2021-11-02 | — | — | US | claimed |
| EP-3324951-B1 | PERITONEAL THERAPEUTIC FLUID | OPTERION HEALTH AG (CH) | 2021-05-26 | — | — | EP | claimed |
| EP-3420072-A1 | CELL CULTURE MEDIUM | Agency for Science, Technology and Research (SG) | 2019-01-02 | — | — | EP | claimed |
| EP-3250051-B1 | A NATURAL SWEETENING COMPOSITION OF LUO HAN GUO AND APPLE | MONTERO GIDA SANAYI VE TICARET AS (TR) | 2018-11-07 | — | — | EP | claimed |
| WO-2017146646-A1 | CELL CULTURE MEDIUM | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-08-31 | — | — | WO | claimed |
| EP-3205336-A1 | TREATMENT OF TISSUE ADHESION | Mallinckrodt Pharma IP Trading D.A.C. (IE) | 2017-08-16 | — | — | EP | claimed |
| US-20170127675-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING INSECT POPULATIONS | OLFACTOR LABORATORIES, INC. (US) | 2017-05-11 | — | — | US | claimed |
| EP-1652527-A1 | ACCELERATOR FOR MINERAL ABSORPTION AND USE THEREOF | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 2006-05-03 | — | — | EP | claimed |
| EP-1192947-B1 | Pharmaceutical composition comprising trehalose for ophthalmic use | HAYASHIBARA BIOCHEM LAB (JP) | 2006-04-19 | — | — | EP | claimed |
| EP-1600143-A1 | SKIN PREPARATION FOR EXTERNAL USE CHARACTERIZED BY CONTAINING SUGAR DERIVATIVE OF a,a-TREHALOSE | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo (JP) | 2005-11-30 | — | — | EP | claimed |
| US-20050215493-A1 | Calcium-containing tissue strengthening agents and use thereof | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 2005-09-29 | — | — | US | claimed |
| EP-1568283-A1 | METHOD OF INHIBITING ACRYLAMIDE FORMATION AND USE THEREOF | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo (JP) | 2005-08-31 | — | — | EP | claimed |
| EP-1514540-A1 | CALCIUM-CONTAINING TISSUE STRENGTHENING AGENTS AND USE THEREOF | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo (JP) | 2005-03-16 | — | — | EP | claimed |
| US-20050054585-A1 | Agent controlling the production of osteoclast formation regulator and method of screening substance capable of controlling the production of osteoclast formation regulator | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKY | 2005-03-10 | — | — | US | claimed |
| US-20050009017-A1 | Alpha-isomaltosyltransferase, process for producing the same and use thereof | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 2005-01-13 | — | — | US | claimed |
| EP-1447085-A1 | AGENT CONTROLLING THE PRODUCTION OF OSTEOCLAST FORMATION REGULATOR AND METHOD OF SCREENING SUBSTANCE CAPABLE OF CONTROLLING THE PRODUCTION OF OSTEOCLAST FORMATION REGULATOR | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo (JP) | 2004-08-18 | — | — | EP | claimed |
| EP-1284286-A1 | ALPHA-ISOMALTOSYLTRANSFERASE, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo (JP) | 2003-02-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11160766-B2 | Peritoneal therapeutic fluid | FABP6, ALB, FABP2 | MEN1 4429/4885KMT2A 2838/4885PTPN1 2090/4885 |
| US-20050215493-A1 | Calcium-containing tissue strengthening agents and use thereof | ATP2A3, ATP2A1, ATP2A2 | MEN1 2080/4885KMT2A 4558/4885PTPN1 4715/4885 |
| US-20050009017-A1 | Alpha-isomaltosyltransferase, process for producing the same and use thereof | UGGT1, B4GALT1, GALE | MEN1 2624/4885KMT2A 2370/4885PTPN1 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.